StockMacro
Menu

Amneal Pharmaceuticals

$21.12 +65% in 6 monthsMarket cap $7.4B

AMRX on XNAS, Health Care, Amneal Pharmaceuticals, Inc., job postings

Measures activity, not value. Not investment advice.

Net income rose 721% to $133.3M while shares gained 83% in twelve months.

  • GoodLatest quarter revenue up 10% to $862.7M from a year earlier
  • WatchCapital spending up 158% to $31.8M in the latest quarter

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Industry
Pharmaceutical preparations (Health Care)
Employees
8,500
Website
amneal.com
Listed
Nasdaq, US
Last results
3 Nov 2026
Next results
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $862.7M, net loss $21.7M.
Quarter to 31 Dec 2021: revenue $536.9M, net income –Quarter to 31 Mar 2022: revenue $497.6M, net income -$8.8MQuarter to 31 Mar 2022: revenue $497.6M, net income -$8.8MQuarter to 30 Jun 2022: revenue $559.4M, net income -$242.1MQuarter to 30 Jun 2022: revenue $559.4M, net income -$242.1MQuarter to 30 Sep 2022: revenue $545.6M, net income -$7.6MQuarter to 30 Sep 2022: revenue $545.6M, net income -$7.6MQuarter to 31 Dec 2022: revenue $609.8M, net income –Quarter to 31 Mar 2023: revenue $557.5M, net income -$15.6MQuarter to 31 Mar 2023: revenue $557.5M, net income -$15.6MQuarter to 30 Jun 2023: revenue $599.0M, net income $22.2MQuarter to 30 Jun 2023: revenue $599.0M, net income $22.2MQuarter to 30 Sep 2023: revenue $620.0M, net income $15.5MQuarter to 30 Sep 2023: revenue $620.0M, net income $15.5MQuarter to 31 Dec 2023: revenue $617.0M, net income -$101.4MQuarter to 31 Dec 2023: revenue $617.0M, net income -$101.4MQuarter to 31 Mar 2024: revenue $659.2M, net income -$91.6MQuarter to 31 Mar 2024: revenue $659.2M, net income -$91.6MQuarter to 30 Jun 2024: revenue $701.8M, net income $6.0MQuarter to 30 Jun 2024: revenue $701.8M, net income $6.0MQuarter to 30 Sep 2024: revenue $702.5M, net income -$156KQuarter to 30 Sep 2024: revenue $702.5M, net income -$156KQuarter to 31 Dec 2024: revenue $730.5M, net income -$20.7MQuarter to 31 Dec 2024: revenue $730.5M, net income -$20.7MQuarter to 31 Mar 2025: revenue $695.4M, net income $12.2MQuarter to 31 Mar 2025: revenue $695.4M, net income $12.2MQuarter to 30 Jun 2025: revenue $724.5M, net income $22.4MQuarter to 30 Jun 2025: revenue $724.5M, net income $22.4MQuarter to 30 Sep 2025: revenue $784.5M, net income $2.4MQuarter to 30 Sep 2025: revenue $784.5M, net income $2.4MQuarter to 31 Dec 2025: revenue $814.3M, net income –Quarter to 31 Mar 2026: revenue $722.5M, net income $62.3MQuarter to 31 Mar 2026: revenue $722.5M, net income $62.3MQuarter to 30 Jun 2026: revenue $796.2M, net income $57.7MQuarter to 30 Jun 2026: revenue $796.2M, net income $57.7MQuarter to 30 Sep 2026: revenue $862.7M, net income -$21.7MQuarter to 30 Sep 2026: revenue $862.7M, net income -$21.7M
31 Dec 2021RevenueNet incomeNet losstallest bar $862.7M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$862.7M-$21.7M
30 Jun 2026$796.2M$57.7M
31 Mar 2026$722.5M$62.3M
31 Dec 2025$814.3M–
30 Sep 2025$784.5M$2.4M
30 Jun 2025$724.5M$22.4M
31 Mar 2025$695.4M$12.2M
31 Dec 2024$730.5M-$20.7M
30 Sep 2024$702.5M-$156K
30 Jun 2024$701.8M$6.0M
31 Mar 2024$659.2M-$91.6M
31 Dec 2023$617.0M-$101.4M
30 Sep 2023$620.0M$15.5M
30 Jun 2023$599.0M$22.2M
31 Mar 2023$557.5M-$15.6M
31 Dec 2022$609.8M–
30 Sep 2022$545.6M-$7.6M
30 Jun 2022$559.4M-$242.1M
31 Mar 2022$497.6M-$8.8M
31 Dec 2021$536.9M–
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $3.2B $2.9B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +8.9% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $133.3M $16.2M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $0.42 $0.02
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 40.2% 36.8% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 15.0% 12.2% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 4.2% 0.6% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $88.2M $264.3M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $157.4M $201.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $2.9B $2.6B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $2.8B $2.4B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 5.5 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.52
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 55.2 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.3 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 3.2 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 13.9 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Amneal PharmaceuticalsAMRX (this company) $7.4B55.22.3+8.9%4.2%
Kiniksa Pharmaceuticals InternationalKNSA $7.4B67.37.8+58%11.6%
AlkermesALKS $7.6Bloss4.3+15%-0.0%
CytokineticsCYTK $7.1Bloss62.4+30%-687%
Rhythm PharmaceuticalsRYTM $7.8Bloss27.7+61%-69.0%
Corcept TherapeuticsCORT $6.9B42.97.2+30%16.8%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+9.6%

332 13F filers vs 303

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

49%

169.2M shares held by 13F filers (30 Sep 2026) of 348.4M outstanding (30 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

3.3%

11.4M shares sold short (30 Oct 2026) of 348.4M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

2.8

11.4M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-19%

14.1M shares sold short in the report before, 11.4M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

74%

74% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 54%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

+33%

57 vs 43 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+10%

$862.7M vs $784.5M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+158%

$31.8M vs $12.3M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$1.1M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

25

25 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

6.2×

25 articles in the last 7 days; its usual week has 4.

Price $21.12 on 20 Nov 2026, +83% over 12 months (12-month range $11.52 to $21.88)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $7.7M in the last 12 months (the 12 months before: -$62.5M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 56 published in the last 12 months, +27% on the 12 months before.
Revenue per quarter. Revenue $862.7M in the latest quarter, +10% on a year earlier.
Capital spending per quarter. Capital spending $31.8M in the latest quarter, +158% on a year earlier.
Institutional holders (13F filers). 332 13F filers reported holding it in the latest 13F quarter, +40% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.
Lobbying spend. Lobbying spend: $1.1M published in the last 12 months, -33% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
8 Oct 2026Lobbying filingnew lobbying registration (HILL EAST GROUP, LLC)
10 Aug 20268-K and other filingsCompleted an acquisition or asset sale
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 69 vs usual 31.50 (2026-03-31); 1.5x the same period a year earlier
12 May 2026Sharp changeShort interest spike: short interest spike, 11.5M vs usual 5.9M (2026-04-30); 1.9x the same period a year earlier
31 Mar 2026Sharp changeShort interest spike: short interest spike, 10.8M vs usual 5.5M (2026-03-13); 3.4x the same period a year earlier
17 Mar 2026Sharp changeShort interest spike: short interest spike, 9.9M vs usual 5.4M (2026-02-27); 3.6x the same period a year earlier
3 Mar 2026Sharp changeShort interest spike: short interest spike, 10.6M vs usual 5.4M (2026-02-13); 4.0x the same period a year earlier
17 Feb 2026Sharp changeShort interest spike: short interest spike, 12.7M vs usual 5.3M (2026-01-30); 5.2x the same period a year earlier
12 Aug 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 22.8M vs usual 11.8M (2025-06-30); 2.1x the same period a year earlier
21 Jul 20258-K and other filingsDirector or officer change
21 Jul 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Jul 2025Lobbying filingnew lobbying registration (FIERCE GOVERNMENT RELATIONS)
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 46 vs usual 27 (2025-03-31); 1.7x the same period a year earlier
21 Apr 2025Sharp changeLobbying on a new issue: lobbying on a new issue: MAN (2025-03-31)
6 Mar 20258-K and other filingsDirector or officer change
6 Mar 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Feb 2025Lobbying filingnew lobbying registration (OGR)
11 Apr 2024Lobbying filingnew lobbying registration (TARPLIN, DOWNS & YOUNG, LLC)
25 Jan 2024Lobbying filingnew lobbying registration (in-house)
15 Dec 20238-K and other filingsDelisting notice or listing transfer
28 Mar 2023Sharp changeShort interest spike: short interest spike, 7.4M vs usual 4.1M (2023-03-15); 2.3x the same period a year earlier
14 Mar 2023Sharp changeShort interest spike: short interest spike, 7.1M vs usual 3.9M (2023-02-28); 2.4x the same period a year earlier
28 Feb 2023Sharp changeShort interest spike: short interest spike, 8.1M vs usual 3.8M (2023-02-15); 2.8x the same period a year earlier
14 Feb 2023Sharp changeShort interest spike: short interest spike, 9.1M vs usual 3.8M (2023-01-31); 4.1x the same period a year earlier
31 Jan 2023Sharp changeShort interest spike: short interest spike, 8.2M vs usual 3.7M (2023-01-13); 3.9x the same period a year earlier
17 Jan 2023Sharp changeShort interest spike: short interest spike, 7.7M vs usual 3.7M (2022-12-30); 2.7x the same period a year earlier
6 Sep 20228-K and other filingsDirector or officer change
3 Aug 20228-K and other filingsDirector or officer change
3 Aug 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Jun 20228-K and other filingsA major agreement ended
20 Apr 2022Lobbying filinglobbying engagement terminated (FIERCE GOVERNMENT RELATIONS)
16 Mar 20228-K and other filingsDirector or officer change
16 Mar 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: $822K published
Month from 1 Dec 2022: -$9.1M published
Month from 1 Aug 2023: -$121K published
Month from 1 May 2024: -$256K published
Month from 1 Aug 2024: -$1.3M published
Month from 1 Nov 2024: -$968K published
Month from 1 Jan 2025: -$641K published
Month from 1 Feb 2025: -$651K published
Month from 1 Mar 2025: -$46.0M published
Month from 1 Apr 2025: -$664K published
Month from 1 May 2025: -$821K published
Month from 1 Jun 2025: -$1.2M published
Month from 1 Aug 2025: -$10.4M published
Month from 1 Nov 2025: -$2.2M published
Month from 1 May 2026: -$451K published
Month from 1 Aug 2026: -$7.2M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 4 published
Quarter from 1 Apr 2022: 4 published
Quarter from 1 Jul 2022: 19 published
Quarter from 1 Oct 2022: 9 published
Quarter from 1 Jan 2023: 8 published
Quarter from 1 Apr 2023: 3 published
Quarter from 1 Jul 2023: 19 published
Quarter from 1 Oct 2023: 5 published
Quarter from 1 Jan 2024: 5 published
Quarter from 1 Apr 2024: 8 published
Quarter from 1 Jul 2024: 15 published
Quarter from 1 Oct 2024: 8 published
Quarter from 1 Jan 2025: 6 published
Quarter from 1 Apr 2025: 6 published
Quarter from 1 Jul 2025: 21 published
Quarter from 1 Oct 2025: 11 published
Quarter from 1 Jan 2026: 5 published
Quarter from 1 Apr 2026: 7 published
Quarter from 1 Jul 2026: 30 published
Quarter from 1 Oct 2026: 14 published
Revenue per quarter
Quarter ended 31 Dec 2021: $536.9M, +5.3% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $497.6M, +0.9% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $559.4M, +4.5% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $545.6M, +3.2% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $609.8M, +14% on a year earlier; public on 4 Mar 2023
Quarter ended 31 Mar 2023: $557.5M, +12% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $599.0M, +7.1% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $620.0M, +14% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $617.0M, +1.2% on a year earlier; public on 15 Mar 2024
Quarter ended 31 Mar 2024: $659.2M, +18% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $701.8M, +17% on a year earlier; public on 10 Aug 2024
Quarter ended 30 Sep 2024: $702.5M, +13% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $730.5M, +18% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $695.4M, +5.5% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $724.5M, +3.2% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $784.5M, +12% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $814.3M, +11% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $722.5M, +3.9% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $796.2M, +9.9% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $862.7M, +10% on a year earlier; public on 10 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $17.5M, -41% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $10.8M, -8.3% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $5.0M, -35% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $19.1M, +79% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $11.5M, -34% on a year earlier; public on 4 Mar 2023
Quarter ended 31 Mar 2023: $9.7M, -10% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $12.0M, +138% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $11.7M, -39% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $9.9M, -14% on a year earlier; public on 15 Mar 2024
Quarter ended 31 Mar 2024: $9.2M, -5.1% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $10.6M, -11% on a year earlier; public on 10 Aug 2024
Quarter ended 30 Sep 2024: $16.9M, +45% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $15.2M, +54% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $13.2M, +43% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $22.8M, +115% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $12.3M, -27% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $21.8M, +44% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $8.2M, -38% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $30.7M, +34% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $31.8M, +158% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 141; public on 14 Feb 2022
31 Mar 2022 report: 161; public on 16 May 2022
30 Jun 2022 report: 149; public on 15 Aug 2022
30 Sep 2022 report: 143; public on 14 Nov 2022
31 Dec 2022 report: 146; public on 14 Feb 2023
31 Mar 2023 report: 139; public on 15 May 2023
30 Jun 2023 report: 124; public on 14 Aug 2023
30 Sep 2023 report: 136; public on 14 Nov 2023
31 Dec 2023 report: 145; public on 14 Feb 2024
31 Mar 2024 report: 168; public on 15 May 2024
30 Jun 2024 report: 174; public on 14 Aug 2024
30 Sep 2024 report: 176; public on 14 Nov 2024
31 Dec 2024 report: 196; public on 14 Feb 2025
31 Mar 2025 report: 225; public on 15 May 2025
30 Jun 2025 report: 228; public on 14 Aug 2025
30 Sep 2025 report: 237; public on 14 Nov 2025
31 Dec 2025 report: 263; public on 17 Feb 2026
31 Mar 2026 report: 309; public on 15 May 2026
30 Jun 2026 report: 303; public on 14 Aug 2026
30 Sep 2026 report: 332; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $28K published
Month from 1 Jan 2022: $152 published
Month from 1 Feb 2022: $451 published
Month from 1 Mar 2022: $81.4 published
Month from 1 Apr 2022: $479K published
Month from 1 May 2022: $3.7 published
Month from 1 Jun 2022: $63.8 published
Month from 1 Aug 2022: $3K published
Month from 1 Sep 2022: $1K published
Month from 1 Dec 2022: $42 published
Month from 1 Jun 2023: $27K published
Month from 1 Oct 2023: $93.1 published
Month from 1 Nov 2023: $189K published
Month from 1 Dec 2023: $2K published
Month from 1 Feb 2024: $4K published
Month from 1 Apr 2024: $246 published
Month from 1 Jun 2024: $31K published
Lobbying spend
Quarter from 1 Jan 2022: $60K published
Quarter from 1 Apr 2022: $40K published
Quarter from 1 Apr 2024: $850K published
Quarter from 1 Jul 2024: $240K published
Quarter from 1 Oct 2024: $230K published
Quarter from 1 Jan 2025: $210K published
Quarter from 1 Apr 2025: $910K published
Quarter from 1 Jul 2025: $220K published
Quarter from 1 Oct 2025: $360K published
Quarter from 1 Jan 2026: $390K published
Quarter from 1 Apr 2026: $240K published
Quarter from 1 Jul 2026: $240K published
Quarter from 1 Oct 2026: $270K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $862.7M (30 Sep 2026), 1.2× its normal quarter; higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $7.7M in the last 12 months (the 12 months before: -$62.5M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 56 published in the last 12 months, +27% on the 12 months before.
  • Revenue per quarter: Revenue $862.7M in the latest quarter, +10% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 68 insider trades

No trades in the last 90 days; the latest was filed 14 Aug 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
14 Aug 2026John KielyDirectorSell50,000$17.64$882KForm 4
13 Aug 2026Nikita ShahExecutive Vice PresidentSell146,403$17.51$2.6MForm 4
13 Aug 2026Jason B. DalyEVP, Chief Legal OfficerSell216,613$17.41$3.8MForm 4
12 May 2026Deborah M. AutorDirectorSell34,819$12.94$451KForm 4
19 Nov 2025Ted C NarkDirectorSell50,000$11.72$586KForm 4
14 Nov 2025Nikita ShahExecutive Vice PresidentSellafter exercising options131,856$11.92$1.6MForm 4
28 Aug 2025John KielyDirectorSell32,000$9.23$295KForm 4
25 Aug 2025Nikita ShahExecutive Vice PresidentSell120,832$9.65$1.2MForm 4

332 institutions reported shares at the end of Q3 2026, 49% of the shares outstanding; 55 opened a position, 30 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.26.9M7.71%$541.3M+315K+1.2%
Vanguard Portfolio Management LLC12.4M3.55%$249.0M+228K+1.9%
TPG GP A, LLC12.3M3.54%$248.3MNo change
Rubric Capital Management LP8.5M2.45%$171.9M-1.6M-16%
Vanguard Capital Management LLC8.0M2.29%$160.9M+278K+3.6%
State Street Corp7.5M2.14%$150.5M+114K+1.6%
Citadel Advisors LLC7.0M2.01%$140.9M+5.9M+525%
Invesco Ltd.6.0M1.71%$120.1M+2.5M+70%
Dimensional Fund Advisors LP5.8M1.67%$117.1M+22K+0.4%
Geode Capital Management, LLC4.6M1.31%$92.0M-571K-11%

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 8 Jan 2021. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
8 Jan 2021Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$2.2MFUNDING RECEIVE TO PURCHASE 20,0000 AUTO INJECTORSUSAspending

Company events

All 41 company events

In 12 months: 4 major agreements, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
10 Aug 2026Signed a major agreement; Completed an acquisition or asset saleSame filing: took on new debt, sold shares privately8-K
3 Aug 2026Signed a major agreement8-K
22 Apr 2026Signed a major agreementSame filing: sold shares privately8-K
2 Feb 2026Signed a major agreementSame filing: took on new debt8-K
1 Aug 2025Signed a major agreementSame filing: took on new debt8-K
21 Jul 2025Director or officer change8-K
6 Mar 2025Director or officer change8-K
15 Dec 2023Delisting notice or listing transfer8-K

Reported lobbying spend: $270K in Q3 2026, $240K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Sep 2026NewHill East Group, LLCfor Avkare, LLCIssues related to domestic generic pharmaceutical manufacturingManufacturing, Health issuesFiling
15 Jun 2025NewFierce Government Relationsfor Atlas FRM LLC (D/B/A Atlas Holdings LLC)Tariffs, 232 steel investigation.Manufacturing, TradeFiling
1 Jan 2025NewOgrfor Amneal Pharmaceuticals LLCAdvocate for the importance of maintaining strong domestic manufacturing industry.ManufacturingFiling
1 Jan 2024NewTarplin, Downs & Young, LLCfor Amneal Pharmaceuticals, Inc.drug shortages, preparednessHealth issues, Medicare/MedicaidFiling
1 Jan 2024NewAmneal Pharmaceuticalsits own lobbyistsIssues related to accessible medicines; marketplace issues; Issues related to economics of manufacturing essential medicines.Health issuesFiling
28 Feb 2022EndedFierce Government Relationsfor Amneal PharmaceuticalsSupply Chain, S. 1176- Onshoring Essential Antibiotics Act, Pandemic Preparedness ActPharmacyFiling
15 Apr 2020NewFierce Government Relationsfor Amneal PharmaceuticalsIssues related to the generic drug industryHealth issues, Medicare/MedicaidFiling
1 Feb 2019EndedBrown Rudnick LLPfor Amneal PharmaceuticalsNot statedFiling

Layoff notices

All 1 layoff notices

No notice in 12 months; the latest is dated 1 Feb 2017. State WARN notices.

NoticeSiteWorkersJobs endSource
1 Feb 2017Impax LaboratoriesMiddlesex, NJ20715 Mar 2017Notice

The 5 newest of 244 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

19 May 2026confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Amneal Pharmaceuticals (AMRX): had 11.5M shares sold short in the 30 Apr 2026 report, 1.9× the same report last year, while it saw 69 13F filers open a new position in the quarter ended 31 Mar 2026, 1.5× the same quarter last year. Two unrelated kinds of activity within 7 days.

  • Short interest and volume: Short interest spike, became public on 12 May 2026
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2026
2025-04-30: 6.1M2025-05-15: 5.4M2025-05-30: 4.2M2025-06-13: 5.4M2025-06-30: 6.6M2025-07-15: 5.4M2025-07-31: 4.9M2025-08-15: 4.8M2025-08-29: 5.1M2025-09-15: 5.0M2025-09-30: 5.7M2025-10-15: 5.8M2025-10-31: 5.6M2025-11-14: 6.6M2025-11-28: 6.1M2025-12-15: 5.3M2025-12-31: 6.9M2026-01-15: 6.8M2026-01-30: 12.7M2026-02-13: 10.6M2026-02-27: 9.9M2026-03-13: 10.8M2026-03-31: 7.2M2026-04-15: 8.6M2026-04-30: 11.5M
The 30 Apr 2026 report against the 24 reports before it. this reportearliernormal: 5.9M
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 12 May 2026

Amneal Pharmaceuticals had 11.5M shares sold short in the 30 Apr 2026 report, 1.9× the same report last year.

This period
11.5M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
5.9M
Typical spread (median absolute deviation)
832K
How far from its usual level
+4.5
Same report last year
6.1M
History used
2,907 days
2025-04-30: 6.1M2025-05-15: 5.4M2025-05-30: 4.2M2025-06-13: 5.4M2025-06-30: 6.6M2025-07-15: 5.4M2025-07-31: 4.9M2025-08-15: 4.8M2025-08-29: 5.1M2025-09-15: 5.0M2025-09-30: 5.7M2025-10-15: 5.8M2025-10-31: 5.6M2025-11-14: 6.6M2025-11-28: 6.1M2025-12-15: 5.3M2025-12-31: 6.9M2026-01-15: 6.8M2026-01-30: 12.7M2026-02-13: 10.6M2026-02-27: 9.9M2026-03-13: 10.8M2026-03-31: 7.2M2026-04-15: 8.6M2026-04-30: 11.5M
the 30 Apr 2026 report24 earlier reportsnormal: 5.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 15 May 2026

Amneal Pharmaceuticals saw 69 13F filers open a new position in the quarter ended 31 Mar 2026, 1.5× the same quarter last year.

This period
69 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
31.5
Typical spread (median absolute deviation)
4
How far from its usual level
+6.3
Same quarter last year
46
History used
2,831 days
2024-03-31: 272024-06-30: 292024-09-30: 232024-12-31: 322025-03-31: 462025-06-30: 312025-09-30: 352025-12-31: 412026-03-31: 69
the quarter ended 31 Mar 20268 earlier quartersnormal: 31.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

15 May 2025confirmed

Confirmed across sources Institutional holdings and Lobbying

Amneal Pharmaceuticals (AMRX): lobbying on a new issue, while it saw 46 13F filers open a new position in the quarter ended 31 Mar 2025, 1.7× the same quarter last year. Two unrelated kinds of activity within 24 days.

  • Lobbying: Lobbying on a new issue, became public on 21 Apr 2025
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2025
2023-03-31: 92023-06-30: 112023-09-30: 272023-12-31: 282024-03-31: 272024-06-30: 292024-09-30: 232024-12-31: 322025-03-31: 46
The quarter ended 31 Mar 2025 against the 8 quarters before it. this quarterearliernormal: 27
See the evidence (2 changes)

Lobbying: Lobbying on a new issue became public on 21 Apr 2025

Amneal Pharmaceuticals lobbying on a new issue.

New
['MAN']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6138169

Institutional holdings: Many funds opening a new position became public on 15 May 2025

Amneal Pharmaceuticals saw 46 13F filers open a new position in the quarter ended 31 Mar 2025, 1.7× the same quarter last year.

This period
46 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
27
Typical spread (median absolute deviation)
3
How far from its usual level
+4.3
Same quarter last year
27
History used
2,466 days
2023-03-31: 92023-06-30: 112023-09-30: 272023-12-31: 282024-03-31: 272024-06-30: 292024-09-30: 232024-12-31: 322025-03-31: 46
the quarter ended 31 Mar 20258 earlier quartersnormal: 27

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 8 Oct 2026Lobbying record

    AVKARE, LLC: new lobbying registration (HILL EAST GROUP, LLC) (dated 1 Sep 2026)

  2. 10 Aug 2026Filings record

    Completed an acquisition or asset sale

  3. 19 May 2026several at once

    had 11.5M shares sold short in the 30 Apr 2026 report, 1.9× the same report last year, while it saw 69 13F filers open a new position in the quarter ended 31 Mar 2026, 1.5× the same quarter last year. Two unrelated kinds of activity within 7 days.

    See the evidence (2 changes)

    Short interest and volume: Short interest spike became public on 12 May 2026

    Amneal Pharmaceuticals had 11.5M shares sold short in the 30 Apr 2026 report, 1.9× the same report last year.

    This period
    11.5M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    5.9M
    Typical spread (median absolute deviation)
    832K
    How far from its usual level
    +4.5
    Same report last year
    6.1M
    History used
    2,907 days
    2025-04-30: 6.1M2025-05-15: 5.4M2025-05-30: 4.2M2025-06-13: 5.4M2025-06-30: 6.6M2025-07-15: 5.4M2025-07-31: 4.9M2025-08-15: 4.8M2025-08-29: 5.1M2025-09-15: 5.0M2025-09-30: 5.7M2025-10-15: 5.8M2025-10-31: 5.6M2025-11-14: 6.6M2025-11-28: 6.1M2025-12-15: 5.3M2025-12-31: 6.9M2026-01-15: 6.8M2026-01-30: 12.7M2026-02-13: 10.6M2026-02-27: 9.9M2026-03-13: 10.8M2026-03-31: 7.2M2026-04-15: 8.6M2026-04-30: 11.5M
    the 30 Apr 2026 report24 earlier reportsnormal: 5.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 15 May 2026

    Amneal Pharmaceuticals saw 69 13F filers open a new position in the quarter ended 31 Mar 2026, 1.5× the same quarter last year.

    This period
    69 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    31.5
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +6.3
    Same quarter last year
    46
    History used
    2,831 days
    2024-03-31: 272024-06-30: 292024-09-30: 232024-12-31: 322025-03-31: 462025-06-30: 312025-09-30: 352025-12-31: 412026-03-31: 69
    the quarter ended 31 Mar 20268 earlier quartersnormal: 31.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  4. 15 May 2026Institutional holdings change

    saw 69 13F filers open a new position in the quarter ended 31 Mar 2026, 1.5× the same quarter last year.

    Same quarter last year: 46; its normal quarter is 31.5.

    See the evidence
    This period
    69 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    31.5
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +6.3
    Same quarter last year
    46
    History used
    2,831 days
    2024-03-31: 272024-06-30: 292024-09-30: 232024-12-31: 322025-03-31: 462025-06-30: 312025-09-30: 352025-12-31: 412026-03-31: 69
    the quarter ended 31 Mar 20268 earlier quartersnormal: 31.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  5. 12 May 2026Short interest and volume change

    had 11.5M shares sold short in the 30 Apr 2026 report, 1.9× the same report last year.

    Same report last year: 6.1M; its normal report is 5.9M.

    See the evidence
    This period
    11.5M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    5.9M
    Typical spread (median absolute deviation)
    832K
    How far from its usual level
    +4.5
    Same report last year
    6.1M
    History used
    2,907 days
    2025-04-30: 6.1M2025-05-15: 5.4M2025-05-30: 4.2M2025-06-13: 5.4M2025-06-30: 6.6M2025-07-15: 5.4M2025-07-31: 4.9M2025-08-15: 4.8M2025-08-29: 5.1M2025-09-15: 5.0M2025-09-30: 5.7M2025-10-15: 5.8M2025-10-31: 5.6M2025-11-14: 6.6M2025-11-28: 6.1M2025-12-15: 5.3M2025-12-31: 6.9M2026-01-15: 6.8M2026-01-30: 12.7M2026-02-13: 10.6M2026-02-27: 9.9M2026-03-13: 10.8M2026-03-31: 7.2M2026-04-15: 8.6M2026-04-30: 11.5M
    the 30 Apr 2026 report24 earlier reportsnormal: 5.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 25 Mar 2026Short interest and volume change

    had 10.8M shares sold short in the 13 Mar 2026 report, 3.4× the same report last year.

    Same report last year: 3.2M; its normal report is 5.5M.

    See the evidence
    This period
    10.8M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    5.5M
    Typical spread (median absolute deviation)
    616K
    How far from its usual level
    +5.9
    Same report last year
    3.2M
    History used
    2,859 days
    2025-03-14: 3.2M2025-03-31: 4.4M2025-04-15: 4.9M2025-04-30: 6.1M2025-05-15: 5.4M2025-05-30: 4.2M2025-06-13: 5.4M2025-06-30: 6.6M2025-07-15: 5.4M2025-07-31: 4.9M2025-08-15: 4.8M2025-08-29: 5.1M2025-09-15: 5.0M2025-09-30: 5.7M2025-10-15: 5.8M2025-10-31: 5.6M2025-11-14: 6.6M2025-11-28: 6.1M2025-12-15: 5.3M2025-12-31: 6.9M2026-01-15: 6.8M2026-01-30: 12.7M2026-02-13: 10.6M2026-02-27: 9.9M2026-03-13: 10.8M
    the 13 Mar 2026 report24 earlier reportsnormal: 5.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 11 Mar 2026Short interest and volume change

    had 9.9M shares sold short in the 27 Feb 2026 report, 3.6× the same report last year.

    Same report last year: 2.8M; its normal report is 5.4M.

    See the evidence
    This period
    9.9M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    5.4M
    Typical spread (median absolute deviation)
    660K
    How far from its usual level
    +4.6
    Same report last year
    2.8M
    History used
    2,845 days
    2025-02-28: 2.8M2025-03-14: 3.2M2025-03-31: 4.4M2025-04-15: 4.9M2025-04-30: 6.1M2025-05-15: 5.4M2025-05-30: 4.2M2025-06-13: 5.4M2025-06-30: 6.6M2025-07-15: 5.4M2025-07-31: 4.9M2025-08-15: 4.8M2025-08-29: 5.1M2025-09-15: 5.0M2025-09-30: 5.7M2025-10-15: 5.8M2025-10-31: 5.6M2025-11-14: 6.6M2025-11-28: 6.1M2025-12-15: 5.3M2025-12-31: 6.9M2026-01-15: 6.8M2026-01-30: 12.7M2026-02-13: 10.6M2026-02-27: 9.9M
    the 27 Feb 2026 report24 earlier reportsnormal: 5.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 26 Feb 2026Short interest and volume change

    had 10.6M shares sold short in the 13 Feb 2026 report, 4.0× the same report last year.

    Same report last year: 2.6M; its normal report is 5.4M.

    See the evidence
    This period
    10.6M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    5.4M
    Typical spread (median absolute deviation)
    660K
    How far from its usual level
    +5.4
    Same report last year
    2.6M
    History used
    2,831 days
    2025-02-14: 2.6M2025-02-28: 2.8M2025-03-14: 3.2M2025-03-31: 4.4M2025-04-15: 4.9M2025-04-30: 6.1M2025-05-15: 5.4M2025-05-30: 4.2M2025-06-13: 5.4M2025-06-30: 6.6M2025-07-15: 5.4M2025-07-31: 4.9M2025-08-15: 4.8M2025-08-29: 5.1M2025-09-15: 5.0M2025-09-30: 5.7M2025-10-15: 5.8M2025-10-31: 5.6M2025-11-14: 6.6M2025-11-28: 6.1M2025-12-15: 5.3M2025-12-31: 6.9M2026-01-15: 6.8M2026-01-30: 12.7M2026-02-13: 10.6M
    the 13 Feb 2026 report24 earlier reportsnormal: 5.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 11 Feb 2026Short interest and volume change

    had 12.7M shares sold short in the 30 Jan 2026 report, 5.2× the same report last year.

    Same report last year: 2.4M; its normal report is 5.3M.

    See the evidence
    This period
    12.7M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    5.3M
    Typical spread (median absolute deviation)
    660K
    How far from its usual level
    +7.5
    Same report last year
    2.4M
    History used
    2,817 days
    2025-01-31: 2.4M2025-02-14: 2.6M2025-02-28: 2.8M2025-03-14: 3.2M2025-03-31: 4.4M2025-04-15: 4.9M2025-04-30: 6.1M2025-05-15: 5.4M2025-05-30: 4.2M2025-06-13: 5.4M2025-06-30: 6.6M2025-07-15: 5.4M2025-07-31: 4.9M2025-08-15: 4.8M2025-08-29: 5.1M2025-09-15: 5.0M2025-09-30: 5.7M2025-10-15: 5.8M2025-10-31: 5.6M2025-11-14: 6.6M2025-11-28: 6.1M2025-12-15: 5.3M2025-12-31: 6.9M2026-01-15: 6.8M2026-01-30: 12.7M
    the 30 Jan 2026 report24 earlier reportsnormal: 5.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 12 Aug 2025Financials change

    spent $22.8M on capital projects in the quarter ended 30 Jun 2025, 2.1× the same quarter last year.

    Same quarter last year: $10.6M; its normal quarter is $11.8M.

    See the evidence
    This period
    $22.8M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $11.8M
    Typical spread (median absolute deviation)
    $1.6M
    How far from its usual level
    +4.5
    Same quarter last year
    $10.6M
    History used
    2,830 days
    2023-06-30: $12.0M2023-09-30: $11.7M2023-12-31: $9.9M2024-03-31: $9.2M2024-06-30: $10.6M2024-09-30: $16.9M2024-12-31: $15.2M2025-03-31: $13.2M2025-06-30: $22.8M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $11.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  11. 21 Jul 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 21 Jul 2025Filings record

    Director or officer change

  13. 2 Jul 2025Lobbying record

    ATLAS FRM LLC (D/B/A ATLAS HOLDINGS LLC): new lobbying registration (FIERCE GOVERNMENT RELATIONS) (dated 15 Jun 2025)

  14. 15 May 2025several at once

    lobbying on a new issue, while it saw 46 13F filers open a new position in the quarter ended 31 Mar 2025, 1.7× the same quarter last year. Two unrelated kinds of activity within 24 days.

    See the evidence (2 changes)

    Lobbying: Lobbying on a new issue became public on 21 Apr 2025

    Amneal Pharmaceuticals lobbying on a new issue.

    New
    ['MAN']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6138169

    Institutional holdings: Many funds opening a new position became public on 15 May 2025

    Amneal Pharmaceuticals saw 46 13F filers open a new position in the quarter ended 31 Mar 2025, 1.7× the same quarter last year.

    This period
    46 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    27
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +4.3
    Same quarter last year
    27
    History used
    2,466 days
    2023-03-31: 92023-06-30: 112023-09-30: 272023-12-31: 282024-03-31: 272024-06-30: 292024-09-30: 232024-12-31: 322025-03-31: 46
    the quarter ended 31 Mar 20258 earlier quartersnormal: 27

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  15. 15 May 2025Institutional holdings change

    saw 46 13F filers open a new position in the quarter ended 31 Mar 2025, 1.7× the same quarter last year.

    Same quarter last year: 27; its normal quarter is 27.

    See the evidence
    This period
    46 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    27
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +4.3
    Same quarter last year
    27
    History used
    2,466 days
    2023-03-31: 92023-06-30: 112023-09-30: 272023-12-31: 282024-03-31: 272024-06-30: 292024-09-30: 232024-12-31: 322025-03-31: 46
    the quarter ended 31 Mar 20258 earlier quartersnormal: 27

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  16. 21 Apr 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['MAN']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6138169
  17. 6 Mar 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 6 Mar 2025Filings record

    Director or officer change

  19. 14 Feb 2025Lobbying record

    AMNEAL PHARMACEUTICALS LLC: new lobbying registration (OGR) (dated 1 Jan 2025)

  20. 11 Apr 2024Lobbying record

    AMNEAL PHARMACEUTICALS, INC.: new lobbying registration (TARPLIN, DOWNS & YOUNG, LLC) (dated 1 Jan 2024)

  21. 25 Jan 2024Lobbying record

    AMNEAL PHARMACEUTICALS: new lobbying registration (in-house) (dated 1 Jan 2024)

  22. 15 Dec 2023Filings record

    Delisting notice or listing transfer

  23. 25 Mar 2023Short interest and volume change

    had 7.4M shares sold short in the 15 Mar 2023 report, 2.3× the same report last year.

    Same report last year: 3.2M; its normal report is 4.1M.

    See the evidence
    This period
    7.4M (the 15 Mar 2023 report)
    Normal report (median of 24 earlier)
    4.1M
    Typical spread (median absolute deviation)
    614K
    How far from its usual level
    +3.7
    Same report last year
    3.2M
    History used
    1,765 days
    2022-03-15: 3.2M2022-03-31: 3.2M2022-04-14: 3.4M2022-04-29: 3.8M2022-05-13: 3.9M2022-05-31: 4.2M2022-06-15: 4.2M2022-06-30: 3.8M2022-07-15: 3.6M2022-07-29: 3.4M2022-08-15: 3.7M2022-08-31: 4.0M2022-09-15: 4.6M2022-09-30: 4.7M2022-10-14: 4.8M2022-10-31: 4.7M2022-11-15: 4.3M2022-11-30: 3.6M2022-12-15: 3.2M2022-12-30: 7.7M2023-01-13: 8.2M2023-01-31: 9.1M2023-02-15: 8.1M2023-02-28: 7.1M2023-03-15: 7.4M
    the 15 Mar 2023 report24 earlier reportsnormal: 4.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 10 Mar 2023Short interest and volume change

    had 7.1M shares sold short in the 28 Feb 2023 report, 2.4× the same report last year.

    Same report last year: 2.9M; its normal report is 3.9M.

    See the evidence
    This period
    7.1M (the 28 Feb 2023 report)
    Normal report (median of 24 earlier)
    3.9M
    Typical spread (median absolute deviation)
    598K
    How far from its usual level
    +3.6
    Same report last year
    2.9M
    History used
    1,750 days
    2022-02-28: 2.9M2022-03-15: 3.2M2022-03-31: 3.2M2022-04-14: 3.4M2022-04-29: 3.8M2022-05-13: 3.9M2022-05-31: 4.2M2022-06-15: 4.2M2022-06-30: 3.8M2022-07-15: 3.6M2022-07-29: 3.4M2022-08-15: 3.7M2022-08-31: 4.0M2022-09-15: 4.6M2022-09-30: 4.7M2022-10-14: 4.8M2022-10-31: 4.7M2022-11-15: 4.3M2022-11-30: 3.6M2022-12-15: 3.2M2022-12-30: 7.7M2023-01-13: 8.2M2023-01-31: 9.1M2023-02-15: 8.1M2023-02-28: 7.1M
    the 28 Feb 2023 report24 earlier reportsnormal: 3.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 28 Feb 2023Short interest and volume change

    had 8.1M shares sold short in the 15 Feb 2023 report, 2.8× the same report last year.

    Same report last year: 2.9M; its normal report is 3.8M.

    See the evidence
    This period
    8.1M (the 15 Feb 2023 report)
    Normal report (median of 24 earlier)
    3.8M
    Typical spread (median absolute deviation)
    542K
    How far from its usual level
    +5.2
    Same report last year
    2.9M
    History used
    1,737 days
    2022-02-15: 2.9M2022-02-28: 2.9M2022-03-15: 3.2M2022-03-31: 3.2M2022-04-14: 3.4M2022-04-29: 3.8M2022-05-13: 3.9M2022-05-31: 4.2M2022-06-15: 4.2M2022-06-30: 3.8M2022-07-15: 3.6M2022-07-29: 3.4M2022-08-15: 3.7M2022-08-31: 4.0M2022-09-15: 4.6M2022-09-30: 4.7M2022-10-14: 4.8M2022-10-31: 4.7M2022-11-15: 4.3M2022-11-30: 3.6M2022-12-15: 3.2M2022-12-30: 7.7M2023-01-13: 8.2M2023-01-31: 9.1M2023-02-15: 8.1M
    the 15 Feb 2023 report24 earlier reportsnormal: 3.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 10 Feb 2023Short interest and volume change

    had 9.1M shares sold short in the 31 Jan 2023 report, 4.1× the same report last year.

    Same report last year: 2.2M; its normal report is 3.8M.

    See the evidence
    This period
    9.1M (the 31 Jan 2023 report)
    Normal report (median of 24 earlier)
    3.8M
    Typical spread (median absolute deviation)
    542K
    How far from its usual level
    +6.6
    Same report last year
    2.2M
    History used
    1,722 days
    2022-01-31: 2.2M2022-02-15: 2.9M2022-02-28: 2.9M2022-03-15: 3.2M2022-03-31: 3.2M2022-04-14: 3.4M2022-04-29: 3.8M2022-05-13: 3.9M2022-05-31: 4.2M2022-06-15: 4.2M2022-06-30: 3.8M2022-07-15: 3.6M2022-07-29: 3.4M2022-08-15: 3.7M2022-08-31: 4.0M2022-09-15: 4.6M2022-09-30: 4.7M2022-10-14: 4.8M2022-10-31: 4.7M2022-11-15: 4.3M2022-11-30: 3.6M2022-12-15: 3.2M2022-12-30: 7.7M2023-01-13: 8.2M2023-01-31: 9.1M
    the 31 Jan 2023 report24 earlier reportsnormal: 3.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 26 Jan 2023Short interest and volume change

    had 8.2M shares sold short in the 13 Jan 2023 report, 3.9× the same report last year.

    Same report last year: 2.1M; its normal report is 3.7M.

    See the evidence
    This period
    8.2M (the 13 Jan 2023 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    532K
    How far from its usual level
    +5.7
    Same report last year
    2.1M
    History used
    1,704 days
    2022-01-14: 2.1M2022-01-31: 2.2M2022-02-15: 2.9M2022-02-28: 2.9M2022-03-15: 3.2M2022-03-31: 3.2M2022-04-14: 3.4M2022-04-29: 3.8M2022-05-13: 3.9M2022-05-31: 4.2M2022-06-15: 4.2M2022-06-30: 3.8M2022-07-15: 3.6M2022-07-29: 3.4M2022-08-15: 3.7M2022-08-31: 4.0M2022-09-15: 4.6M2022-09-30: 4.7M2022-10-14: 4.8M2022-10-31: 4.7M2022-11-15: 4.3M2022-11-30: 3.6M2022-12-15: 3.2M2022-12-30: 7.7M2023-01-13: 8.2M
    the 13 Jan 2023 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 12 Jan 2023Short interest and volume change

    had 7.7M shares sold short in the 30 Dec 2022 report, 2.7× the same report last year.

    Same report last year: 2.8M; its normal report is 3.7M.

    See the evidence
    This period
    7.7M (the 30 Dec 2022 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    494K
    How far from its usual level
    +5.5
    Same report last year
    2.8M
    History used
    1,690 days
    2021-12-15: 2.8M2022-01-14: 2.1M2022-01-31: 2.2M2022-02-15: 2.9M2022-02-28: 2.9M2022-03-15: 3.2M2022-03-31: 3.2M2022-04-14: 3.4M2022-04-29: 3.8M2022-05-13: 3.9M2022-05-31: 4.2M2022-06-15: 4.2M2022-06-30: 3.8M2022-07-15: 3.6M2022-07-29: 3.4M2022-08-15: 3.7M2022-08-31: 4.0M2022-09-15: 4.6M2022-09-30: 4.7M2022-10-14: 4.8M2022-10-31: 4.7M2022-11-15: 4.3M2022-11-30: 3.6M2022-12-15: 3.2M2022-12-30: 7.7M
    the 30 Dec 2022 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 6 Sep 2022Filings record

    Director or officer change

  30. 3 Aug 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  31. 3 Aug 2022Filings record

    Director or officer change

  32. 2 Jun 2022Filings record

    A major agreement ended

  33. 20 Apr 2022Lobbying record

    AMNEAL PHARMACEUTICALS: lobbying engagement terminated (FIERCE GOVERNMENT RELATIONS) (dated 28 Feb 2022)

  34. 16 Mar 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 16 Mar 2022Filings record

    Director or officer change

  36. 21 Dec 2021Insiders record

    Patel Gautam (director) bought 50,000 shares of AMRX ($210,500) (dated 20 Dec 2021)

  37. 18 Dec 2021Insiders record

    Patel Chintu (Co-CEO) bought 150,000 shares of AMRX ($625,500) (dated 17 Dec 2021)

  38. 18 Dec 2021Insiders record

    Patel Chirag K. (President & Co-CEO) bought 150,000 shares of AMRX [same transaction as an earlier filing] (dated 17 Dec 2021)

  39. 2 Mar 2021Financials change

    spent $29.5M on capital projects in the quarter ended 31 Dec 2020, 6.5× the same quarter last year.

    Same quarter last year: $4.5M; its normal quarter is $11.3M.

    See the evidence
    This period
    $29.5M (the quarter ended 31 Dec 2020)
    Normal quarter (median of 8 earlier)
    $11.3M
    Typical spread (median absolute deviation)
    $3.4M
    How far from its usual level
    +3.7
    Same quarter last year
    $4.5M
    History used
    1,188 days
    2018-12-31: $20.0M2019-03-31: $18.0M2019-06-30: $11.6M2019-09-30: $13.0M2019-12-31: $4.5M2020-03-31: $7.4M2020-06-30: $8.6M2020-09-30: $11.0M2020-12-31: $29.5M
    the quarter ended 31 Dec 20208 earlier quartersnormal: $11.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  40. 14 Jan 2021Government contracts change

    won its first federal award in our data, a $2.2M Department of Health and Human Services contract.

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2007
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

Showing the newest 40 of 93 entries; narrow the window or the kind of data to see older ones.

Not listed: 148 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001723128
Ticker
AMRX
Domain
amneal.com
Employer name
AMNEAL PHARMACEUTICALS LLC, AMNEAL PHARMACEUTICALS OF NEW YORK, Impax Laboratories (3 unverified)
Lobbying client
amneal pharmaceuticals, atlas frm llc d b a atlas holdings, brown rudnick llp on behalf of amneal pharmaceuticals
Name
Amedra Pharmaceuticals LLC, Amneal Biopharma Solutions Private Limited, Amneal Biopharma Synthesis Private Limited, Amneal Biosciences LLC and 29 more
Uei
HCARMCN67GH6, LVEBAQTPN615, NBK9JTF9JHL4, THNFXMFLGE75 and 1 more
Wikidata
Q16996714
Wikipedia
Amneal Pharmaceuticals
  • DOL H-1B labor condition applications and PERM certifications772 data points1 Oct 2019 to 7 Sep 2026
  • Federal lobbying disclosures (LDA)11 records, 123 data points8 Nov 2013 to 30 Sep 2026
  • SEC Form 13F institutional holdings306 data points30 Jun 2018 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)130 records7 Mar 2018 to 9 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)626 data points31 Dec 2015 to 30 Oct 2026
  • SEC Form 4 insider transactions68 records, 200 data points8 May 2018 to 14 Aug 2026
  • FINRA short interest (twice monthly)608 data points15 May 2018 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 765 data points31 Jul 2018 to 8 Mar 2024
  • WARN layoff notices (state labor agencies)1 record, 3 data points30 Jan 2017 to 1 Feb 2017
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026